ATLANTA--(BUSINESS WIRE)--Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it successfully completed enrollment in its Phase 1b trial of zelpultide alfa for preventive use in very preterm infants at risk for bronchopulmonary dysplasia (BPD).
Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
Airway Therapeutics has dosed the first subject in its Phase Ib clinical trial of zelpultide alfa (rhSP-D) in Spain for preventative usage in very preterm infants who are at bronchopulmonary dysplasia (BPD) risk.
MARIETTA, Ga., Oct. 3, 2022 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced the first patient dosed in Spain in its ongoing Phase 1b Trial of zelpultide alfa (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD). Already active in 10 sites in the U.S., Airway's Europe expansion allows for broader study and accessibility of zelpultide alfa as a potential anti-inflammatory and anti-infective preventative therapy for the serious respiratory disease BPD. In addition to BPD, zelpultide alfa is being studied in an ongoing phase 1b clinical trial for COVID in the U.S.
MARIETTA, Ga., March 31, 2022 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced dosing of the first patient on March 28, 2022 in the Phase 1b randomized trial of AT-100 (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD). The clinical trial will confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
CINCINNATI, Aug. 26, 2021 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients. The clinical trial will confirm the feasibility of intratracheal administrations of AT-100 and its safety and tolerability.
Airway Therapeutics, Inc., a biopharmaceutical company, announced the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to develop AT-100 (rhSP-D) as a treatment for Covid-19. Airway is leveraging the FDA’s Coronavirus Treatment Acceleration Programme (CTAP) that is aimed at evaluating new treatment options for Covid-19.
The US Food and Drug Administration (FDA) has accepted Airway Therapeutics’ Investigational New Drug (IND) application to develop AT-100 (rhSP-D) for treating Covid-19.
Airway Therapeutics, a US-based biopharmaceutical company, announced on April 12, 2021 that FDA has accepted its investigational new drug (IND) application for the development of its novel human recombinant protein, AT-100 (rhSP-D), as a treatment for COVID-19.
CINCINNATI, April 12, 2021 /PRNewswire/ -- Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to develop AT-100 (rhSP-D) as a treatment for COVID-19. Airway is leveraging the FDA's Coronavirus Treatment Acceleration Program (CTAP) that is aimed at evaluating new treatment options for COVID-19.